A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
- Resource Type
- Article
- Authors
- Leroy, Marie; Deramoudt, Laure; Pinturaud, Marine; Demaret, Julie; Alidjinou, Enagnon Kazali; Nudel, Morgane; Cavalieri, Doriane; Chahla, Wadih Abou; Odou, Pascal; Morschhauser, Franck; Yakoub-Agha, Ibrahim; Simon, Nicolas; Beauvais, David
- Source
- Leukemia & Lymphoma. Jun2024, Vol. 65 Issue 6, p868-871. 4p.
- Subject
- *DIFFUSE large B-cell lymphomas
*T cells
- Language
- ISSN
- 1042-8194
This article discusses the efficacy of a second round of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL) who did not respond to the initial treatment. The article highlights the limited treatment options for patients who do not respond to CAR T-cell therapy and presents data from various studies on the efficacy of a second infusion of CAR T-cells. The case study presented in the article demonstrates the potential for a second round of CAR T-cell therapy to achieve a prolonged complete response and the importance of considering a second infusion when B-cells reappear. The article emphasizes the need for further research on the benefits of CAR T-cell reinfusion after initial treatment failure. [Extracted from the article]